Effective virus-mediated gene therapy for
cancer will be facilitated by procedures that enhance the low level of gene transfer mediated by replication-deficient, recombinant viral vectors. We found recently that
protease pretreatment of solid
tumors is a useful strategy for enhancing virus-mediated gene transduction in vivo. In this study, we examined the potential of
protease pretreatment to improve the efficacy of a gene
therapy strategy for
prodrug activation that depends on
infection with a recombinant adenovirus encoding herpes simplex virus
thymidine kinase (Ad-HSV-tk).
Trypsin or a dissolved mixture of
collagenase/
dispase was inoculated into xenografts derived from the human
glioblastoma multiforme-derived cell lines, U87 or U251. Ad-HSV-tk was administered 24 h after
protease pretreatment, and animals were then treated for 10 days with
ganciclovir (GCV). We found that
protease pretreatment increased the efficacy of adenovirus mediated HSV-tk/GCV gene therapy in these experimental
tumor models. Mice receiving Ad-HSV-tk/GCV after
protease pretreatment demonstrated a significantly greater regression of
tumors compared with those treated with Ad-HSV-tk/GCV alone. No adverse effects of
protease pretreatment were observed. No signs of
metastasis were seen either by histological inspection of lymph nodes or by a PCR-based analysis of selected mouse tissues to detect human
tumor cells. Our findings indicate that
protease pretreatment may be a useful strategy to enhance the efficacy of virus-mediated cancer gene
therapy.